Benzinga Pro data, WAVE Life Sciences (NASDAQ:WVE) reported Q2 sales of $375 thousand. Earnings fell to a loss of $41.30 million, resulting in a 9.21% decrease from last quarter. In Q1, WAVE Life Sciences brought in $1.75 million in sales but lost $37.81 million in earnings.

What Is ROCE?

Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q2, WAVE Life Sciences posted an ROCE of -1.06%.

Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.

For WAVE Life Sciences, a negative ROCE ratio of -1.06% suggests that management may not be effectively allocating their capital. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns; poor capital allocation can be a leech on the performance of a company over time.

Analyst Predictions

WAVE Life Sciences reported Q2 earnings per share at $-0.62/share, which did not meet analyst predictions of $-0.39/share.

This article was generated by Benzinga's automated content engine and reviewed by an editor.